VKTX
Viking Therapeutics, Inc.
Stock
$29.94−0.57 (−1.87%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D | $509M | $345M | $102M | $64M | $54M | $45M | $32M | $24M | $19M | $14M | $9.0M | $7.0M | $22M |
| Operating income | −$560M | −$393M | −$151M | −$101M | −$70M | −$56M | −$43M | −$33M | −$26M | −$19M | −$14M | −$12M | −$23M |
| Non-operating income | — | $34M | $41M | $15M | — | — | — | — | — | — | — | — | — |
| Pretax income | — | −$360M | −$110M | −$86M | — | — | — | — | — | — | — | — | — |
| Taxes | — | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — |
| Net income | −$535M | −$360M | −$110M | −$86M | −$69M | −$55M | −$39M | −$26M | −$22M | −$21M | −$15M | −$23M | −$22M |
| Diluted EPS | −$4.66 | −$3.19 | −$1.01 | −$0.91 | −$0.90 | −$0.71 | −$0.54 | −$0.36 | −$0.38 | −$0.79 | −$0.90 | −$3.68 | −$5.23 |
| Diluted shares | — | 112.7M | 109.0M | 94.3M | 76.8M | 77.2M | 72.6M | 72.0M | 57.6M | 26.0M | 16.3M | 6.4M | 4.2M |
| Operating margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — | — |